Newsmeme!
Discover News you didn't know existed
WOMEN who freeze their eggs to delay motherhood are being given false hope by some fertility clinics, an IVF expert has claimed, saying there is no guarantee.
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.The research is significant in helping determine why tamoxifen and other synthetic estrogens are linked to increased rates of endometriosis and uterine cancer, and identifies a pathway that could be ...
SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr.
The largest study to date of endometriosis in pregnant women has found that the condition is a major risk factor for premature birth, the 25th annual conference of the European Society of Human Reproduction and Embryology heard. Dr.
Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr. Chen Chen has been appointed Senior Vice President of Chemistry Services.
( University of California - San Francisco ) University of California - San Francisco researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.
A 22question 'DIY' quiz designed to help women increase their chances of becoming pregnant has been developed by scientists.
Schering-Plough Corp., (NYSE: SGP) announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
AMSTERDAM, THE NETHERLANDS , July 1, 2009 -- Schering-Plough Corp ., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |